All-trans retinoic acid (ATRA) has been proved to be highly During the operation, ATRA levels were measured in sera obtained from the mother and from the neonate, as well as effective in treating acute promyelocytic leukemia (APL), resulting in a complete remission in more than 90% of case from the umbilical cord artery and vein, using the HPLC method previously described by Takitani and colleagues. 4 reports. Recent reports indicate that treatment of APL associated with pregnancy can be successful, 1,2 but because of the Maternal levels of drug measured 2, 4, and 6 h after initiation of the oral administration of 20 mg ATRA. At 2 h, the maternal potential teratogenic effect of ATRA 3 its use in this situation still remains controversial.
level of ATRA was 6 ng/ml, and at 4 h, it was 1 ng/ml; the drug was not detected in serum at 6 h. ATRA was not detected We report the successful use of ATRA in treating APL that was diagnosed in the third trimester of pregnancy. During in sera from the umbilical cord or from the neonate at 2 or 4 h postpartum. ATRA therapy, fetal growth was retarded and fetal arrhythmia was observed. Concentrations of ATRA were measured in Treatment with ATRA was continued, and a complete remission was achieved on day 38. The patient continues to maternal, fetal, and neonatal serum, and the permeability of the placenta was assessed.
receive consolidation chemotherapy with daunorubicin and cytosine arabinoside. The infant developed normally in our A 37-year-old Japanese woman, gravida 1, para1-0-0-0, was observed to have pancytopenia on a routine blood testing neonatal care unit. He did not suffer from apnea or exhibited neurological abnormalities. His weight increased to 3100 g at 29 weeks of gestation. A complete blood count showed a white blood cell count of 1100/l, with 2% atypical promyeand he was discharged 34 days after birth. ATRA has been demonstrated to be teratogenic and mutalocytes, hemoglobin 9.0 g/dl, and thrombocytes 53 000/l. Examination of the bone marrow revealed 53% of the genic. 3 Mahmoud et al 5 reported that eight of nine children who receiving tretinoin at a dose of 45 mg/m 2 per day experinucleated cells to be atypical promyelocytes that stained strongly with myeloperoxidase, confirming the diagnosis of enced serious side-effects; five developed periventricular leukocytosis and three developed retinoic acid syndrome. Harri-APL (French-American-British classification M3). Cytogenetic studies revealed the presence of t(15;17) in all metaphases son et al 1 reported the successful use of ATRA in treating APL, but the neonate in their case developed cardiac arrhythmia studied. Initial coagulation studies demonstrated an elevation of fibrin degradation products (38.0 g/ml), d-dimer (2.0 and sustained cardiac arrest. We assessed the level of ATRA in the maternal, fetal and neonatal serum and investigated the g/ml), partial thromboplastin time (26.8 s), and fibrinogen (217 mg/dl) were all within the normal range. No fetal abnorpermeability of ATRA through the placenta, as well as its accumulation in the fetus. We did not detect ATRA in either malities were detected; the expected fetal body weight based on ultrasonography was 1564 g which was within the approthe umbilical or neonatal serum. Takitani and colleagues   4 reported that the plasma elimination half-life of ATRA is very priate range for 29 weeks' gestation.
The administration of ATRA at a standard dose of 45 short (21-52 min). Muindi et al 6 reported that the continuous daily administration of ATRA was associated with a marked mg/m 2 /day was started at 30 weeks and 1 day gestation. The total thrombocyte count gradually increased on day 18 and decrease in its concentrations from the initial day of therapy to the time of relapse. These findings may explain the low fibrin degradation products decreased to within the normal range on day 22. Hyperleukocytosis did not occur. However, plasma level of ATRA observed in the present case. Animal experiments confirmed the permeability of ATRA through the fetal growth was retarded, and fetal arrhythmia was noted at 33 weeks and 4 days gestation. M-mode echocardiography placenta; 7 therefore, it is possible that ATRA is transported to the fetus directly after administration. revealed abnormal systolic anterior motion of the fetal mitral valve.
The fetus must be closely monitored during ATRA administration with special attention to the risk of arrhythmia. Further An elective cesarean section was performed under general anesthesia at 33 weeks and 6 days gestation, and a male infant studies and long-term follow-up of neonates are needed to confirm the safety of ATRA for the fetus. was delivered. He weighed 1904 g and had an apgar score of 8 at 1 min and of 10 at 5 min. Assisted ventilation was not required. A neonatal electrocardiogram showed blocked atrial premature contractions and arrhythmia, which disappeared by
